Kondareddiar Ramalingam

This inventor holds 47 USPTO granted patents and 8 published patent applications, plus 8 CIPO patents and 5 EPO patents, primarily in Diagnostic Therapeutics. Top assignees: Bracco International Bv, Bracco Suisse Sa, Bracco Imaging S.p.a.. Active years: 1993-2016.

USPTO Granted Patents = 47 (Patent Applications = 8)

% Patents Active = 48.9

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 14

Forward Citations = 616(Granted Patents)

Location History:

North Brunswick, NJ (US) (1993)
Dayton, NJ (US) (1997 - 2016)
Stockbridge, GA (US) (2015 - 2016)

Company Filing History:

21 out of 108

Bracco International Bv

Bracco Imaging S.p.a.

E. R. Squibb Sons, Inc.

patents

where one patent can have more than one assignee

Years Active: 1993-2016

Loading Chart...

Areas of Expertise:

KDR Binding Peptides

VEGF

Fibrin Binding Peptides

Multivalent Constructs

Contrast Agents

Gastrin Releasing Peptides

Endothelial Cell Targeting

Metal Complexes

Chelating Compounds

Hypoxia-Localizing Moiety

Diagnostic Applications

Therapeutic Applications

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9446155 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2016-09-20),

2. 9408926 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2016-08-09),

3. 9333272 - Fibrin binding peptide conjugates for diagnostic and therapeutic applications (2016-05-10),

4. 9056138 - Multivalent constructs for therapeutic and diagnostic applications (2015-06-16),

5. 8663603 - Multivalent constructs for therapeutic and diagnostic applications (2014-03-04),

6. 8642010 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2014-02-04),

7. 8632753 - Multivalent constructs for therapeutic and diagnostic applications (2014-01-21),

8. 8623822 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2014-01-07),

9. 8540966 - Contrast agents endowed with high relaxivity (2013-09-24),

10. 8444954 - Gastrin releasing peptide compounds (2013-05-21),

11. 8420053 - Gastrin releasing peptide compounds (2013-04-16),

12. 8420050 - Gastrin releasing peptide compounds (2013-04-16),

13. 8293214 - Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds (2012-10-23),

14. 8263739 - Compounds for targeting endothelial cells, compositions containing the same and methods for their use (2012-09-11),

15. 8105567 - Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy (2012-01-31),

Title: Innovator Spotlight: Kondareddiar Ramalingam

Introduction: Kondareddiar Ramalingam is a noteworthy inventor located in Dayton, NJ, with an impressive portfolio of 47 patents. His contributions to the field of biotechnology focus on essential therapeutic areas such as angiogenesis, which plays a critical role in various diseases, including cancer.

Latest Patents: Among his latest innovations are the patents for KDR and VEGF/KDR binding peptides and their uses in diagnosis and therapy. These inventions present polypeptides, peptide dimers, and multimeric complexes that include at least one binding moiety for the KDR or VEGF/KDR complex. They possess significant applications in treating, detecting, isolating, or localizing angiogenesis. Particularly noteworthy are the synthetic, isolated polypeptides that bind to the KDR or VEGF/KDR complex with high affinity and the multimeric constructs that incorporate these polypeptides, including their use as contrast agents in medical imaging. Additionally, these patents provide methods for evaluating the effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation.

Career Highlights: Throughout his career, Kondareddiar has made significant strides in the biomedical field. He has worked with reputable companies such as Bracco International Bv and Bracco Suisse Sa, which have allowed him to integrate his innovative thinking with practical applications in healthcare technology.

Collaborations: Kondareddiar Ramalingam has collaborated with esteemed professionals such as Karen E. Linder and Adrian D. Nunn. These collaborations have further propelled his research and development initiatives, leading to the advancement of his patented technologies.

Conclusion: Kondareddiar Ramalingam stands out as a prolific inventor whose work in the development of KDR and VEGF/KDR binding peptides has the potential to facilitate remarkable advancements in medical diagnosis and therapy. His expertise and dedication to innovation contribute significantly to the ongoing fight against diseases related to angiogenesis.